Based on the request of a KOL, Lenis started distributing this medicine 10 years ago as a reimbursed unlicensed Rx medicine in Slovenia even before it had marketing authorization in any country (“Special” status in UK). Due to successful market penetration the product owner decided to register the drug in Slovenia. Over the years, this product has become the standard of care with over 17.000 doses sold in 2022.
Lenis has managed for years to preserve this product’s value in Slovenia and, consequently, through the IRP system, in the region. This resulted in additional revenue for the principal.
Despite a less-than-perfect dossier, Lenis successfully completed product registrations in Serbia and Albania, leading to market exclusivity and a significant sales increase.
Due to well-executed cross-functional efforts of our medical and marketing teams, this drug has become the leading HIV medicine in the region. Soon after the launch, following an early reimbursement, Slovenia has risen to the top 3 countries in the world in market share.